Selected Publications
PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer
Chauhan SS, Casillas AL, Vizzerra AD, Liou H, Clements AN, Flores CE, Prevost CT, Kashatus DF, Snider AJ, Snider JM, Warfel NA. Oncogene. 2023 Dec 14;. doi: 10.1038/s41388-023-02914-0. [Epub ahead of print] PubMed PMID: 38097734.
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Torres-Ayuso P, Katerji M, Mehlich D, Lookingbill SA, Sabbasani VR, Liou H, Casillas AL, Chauhan SS, Serwa R, Rubin MR, Marusiak AA, Swenson RE, Warfel NA, Brognard J. Cell Chem Biol. 2023 Nov 16;. doi: 10.1016/j.chembiol.2023.10.023. PMID: 38016478.
PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion.
Jensen CC, Clements AN, Liou H, Ball LE, Bethard JR, Langlais PR, Toth RK, Chauhan SS, Casillas AL, Daulat SR, Kraft AS, Cress AE, Miranti CK, Mouneimne G, Rogers GC, Warfel NA. J Cell Biol. 2023 Jun 5;222(6). doi: 10.1083/jcb.202208136. Epub 2023 Apr 12. PubMed PMID: 37042842; PubMed Central PMCID: PMC10103708.
Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28.
Toth RK, Solomon R, Warfel NA. Cells. 2022 Mar 16;11(6). doi: 10.3390/cells11061006. PubMed PMID: 35326457; PubMed Central PMCID: PMC8947361.
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. Nat Commun. 2021 Dec 21;12(1):7349. doi: 10.1038/s41467-021-26901-9. PubMed PMID: 34934057; PubMed Central PMCID: PMC8692330.
Casillas AL, Chauhan SS, Toth RK, Sainz AG, Clements AN, Jensen CC, Langlais PR, Miranti CK, Cress AE, Warfel NA. Oncogene. 2021 Aug;40(32):5142-5152. doi: 10.1038/s41388-021-01915-1. Epub 2021 Jul 2. PubMed PMID: 34211090; PubMed Central PMCID: PMC8364516.
Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
Toth RK, Warfel NA. Mol Cancer Ther. 2021 Jan;20(1):3-10. doi: 10.1158/1535-7163.MCT-20-0535. Epub 2020 Dec 10. Review. PubMed PMID: 33303645.
PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer.
Chauhan SS, Toth RK, Jensen CC, Casillas AL, Kashatus DF, Warfel NA. Oncogene. 2020 Mar;39(12):2597-2611. doi: 10.1038/s41388-020-1168-9. Epub 2020 Jan 28. PubMed PMID: 31992853; PubMed Central PMCID: PMC7545584.
Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Am J Clin Exp Urol. 2019;7(4):297-312. eCollection 2019. PubMed PMID: 31511835; PubMed Central PMCID: PMC6734039.